MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

PURPOSE: To determine if BRAF and/or MEK inhibitor-induced GPNMB expression renders melanomas sensitive to CDX-011, an antibody-drug conjugate targeting GPNMB. EXPERIMENTAL DESIGN: The TCGA melanoma dataset was interrogated for a panel of MITF-regulated melanosomal differentiation antigens, includin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Rose, April A. N., Annis, Matthew G., Frederick, Dennie T., Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R., Flaherty, Keith T., Siegel, Peter M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168941/
https://ncbi.nlm.nih.gov/pubmed/27515299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1192
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados